Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00300885
Registration number
NCT00300885
Ethics application status
Date submitted
8/03/2006
Date registered
10/03/2006
Date last updated
4/11/2014
Titles & IDs
Public title
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Query!
Scientific title
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Query!
Secondary ID [1]
0
0
2005-005245-19
Query!
Secondary ID [2]
0
0
11961
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Non-Small Cell Lung
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel
Treatment: Drugs - Carboplatin plus Paclitaxel
Experimental: Sorafenib + C/P - Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), \[400 mg orally, twice daily\] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
Active comparator: Placebo + C/P - Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily\] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
Treatment: Drugs: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel
Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), \[400 mg orally, twice daily\] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
Treatment: Drugs: Carboplatin plus Paclitaxel
Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily\] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS) in Patients Treated With Carboplatin, Paclitaxel and Sorafenib to OS in Patients Treated With Carboplatin, Paclitaxel and Placebo
Query!
Assessment method [1]
0
0
Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks during study treatment and every 3 months during post-treatment.
Query!
Timepoint [1]
0
0
Outcome measure was assessed every 3 weeks starting from randomization, during treatment period and every 3 months during follow-up period until death was recorded or up to data cutoff (1Oct2007) used for planned formal interim analysis
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS determined as time (days) from the date of randomization at start of study to disease progression (radiological or clinical) or death due to any cause, if death occurs before progression.
Query!
Timepoint [1]
0
0
Tumor measurements and assessments based on RECIST criteria were performed every 6 weeks for the first 18 weeks of therapy ( week 6, 12, and 18) and every 12 weeks thereafter up to data cutoff (1Oct2007) used for planned formal interim analysis
Query!
Secondary outcome [2]
0
0
Overall Best Response
Query!
Assessment method [2]
0
0
Best overall tumor response for the ITT population was determined according to Response Evaluation Criteria in Solid Tumors (RECIST). Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased).
Query!
Timepoint [2]
0
0
Tumor measurements and assessments based on RECIST criteria were performed every 6 weeks for the first 18 weeks of therapy ( week 6, 12, and 18) and every 12 weeks thereafter up to data cutoff (1Oct2007) used for planned formal interim analysis
Query!
Secondary outcome [3]
0
0
Duration of Response
Query!
Assessment method [3]
0
0
Duration of response (PR or better) is defined as the time from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented).
Query!
Timepoint [3]
0
0
Tumor measurements and assessments based on RECIST criteria were performed every 6 weeks for the first 18 weeks of therapy ( week 6, 12, and 18) and every 12 weeks thereafter up to data cutoff (1Oct2007) used for planned formal interim analysis
Query!
Secondary outcome [4]
0
0
Patient Reported Outcome as Assessed by FACT-L Score. Change From Baseline in Total FACT-L at Cycles 3,5,7,9 and End of Treatment (EOT)
Query!
Assessment method [4]
0
0
Functional Assessment of Cancer Therapy - Lung cancer subscore (FACT-L). Patient reported outcome as assessed by FACT-L score. FACT-L questionnaire comprises statements about physical, social / family, emotional and functional well-being as well as additional concerns which have to be rated by the patients (0="not at all" to 4="very much"). Cycle duration defined as 21 days. Change from baseline in Total FACT-L on day 1 of cycles 3,5,7,9 (weeks 7,13,19 and 25) and end of treatment (EOT); cycle 1, day 1 used as baseline. EOT is determined by patient's last visit after treatment discontinuation.
Query!
Timepoint [4]
0
0
Outcome measure was assessed on Day 1 of Cycle 1 and Day 1 of every other cycle (i.e. Cycle 3, 5, 7 etc.) during treatment and at end of treatment visit or up to data cutoff (10ct2007) used for planned formal interim analysis
Query!
Secondary outcome [5]
0
0
Patient Reported Outcome as Assessed by LCS Subscale Score. Change From Baseline in LCS Subscale at Cycles 2 Through 9 and at End of Treatment (EOT)
Query!
Assessment method [5]
0
0
Lung Cancer Symptoms (LCS) subscale ranges from 0 (severe debilitation) to 28 (asymptomatic). Cycle duration defined as 21 days. Change from baseline in LCS Subscale on day 1 of cycles 2 through 9 (weeks 4,7,10,13,16,19,22 and 25) and end of treatment (EOT); cycle 1, day 1 used as baseline. EOT is determined by patient's last visit after treatment discontinuation.
Query!
Timepoint [5]
0
0
Outcome measure was assessed on Day 1 of Cycle 1 and Day 1 of every cycle (i.e. Cycle 2, 3, 4, 5 etc.) during treatment and at end of treatment visit or up to data cutoff (10ct2007) used for planned formal interim analysis
Query!
Eligibility
Key inclusion criteria
* Stage IIIB (with effusion) or Stage IV NSCLC any histology
* No prior chemotherapy
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
* Greater than or equal to 18 years of age
* Life expectancy at least 12 weeks
* Adequate bone marrow, liver and renal function
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Prior systemic anti cancer therapy
* Known brain metastasis. Patients with neurological symptoms should undergo at computed tomography (CT) scan/magnetic resonance imaging (MRI) of the brain to exclude brain metastasis
* Pulmonary hemorrhage/bleeding event > Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 within 4 weeks of first dose of study drug
* Thrombotic or embolic events including Transient ischemic attack (TIA) within the past 6 months
* Uncontrolled hypertension
* Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug
* Major surgery within 4 weeks
* Evidence or history of bleeding diathesis or coagulopathy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
926
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
- Port Macquarie
Query!
Recruitment hospital [2]
0
0
- Wollongong
Query!
Recruitment hospital [3]
0
0
- Brisbane
Query!
Recruitment hospital [4]
0
0
- Adelaide
Query!
Recruitment hospital [5]
0
0
- Frankston
Query!
Recruitment hospital [6]
0
0
- Melbourne
Query!
Recruitment hospital [7]
0
0
- Perth
Query!
Recruitment postcode(s) [1]
0
0
2444 - Port Macquarie
Query!
Recruitment postcode(s) [2]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [3]
0
0
4029 - Brisbane
Query!
Recruitment postcode(s) [4]
0
0
5065 - Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [6]
0
0
3144 - Melbourne
Query!
Recruitment postcode(s) [7]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Louisiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Mississippi
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Missouri
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nebraska
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Nevada
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New Jersey
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New York
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
North Dakota
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Ohio
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Oklahoma
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Oregon
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Pennsylvania
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
South Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Tennessee
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Texas
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Utah
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Virginia
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
West Virginia
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Wisconsin
Query!
Country [34]
0
0
Argentina
Query!
State/province [34]
0
0
Buenos Aires
Query!
Country [35]
0
0
Argentina
Query!
State/province [35]
0
0
Ciudad Auton. de Buenos Aires
Query!
Country [36]
0
0
Argentina
Query!
State/province [36]
0
0
Santa Fe
Query!
Country [37]
0
0
Argentina
Query!
State/province [37]
0
0
Capital Federal-Buenos Aires
Query!
Country [38]
0
0
Argentina
Query!
State/province [38]
0
0
Santa Fé
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Bruxelles - Brussel
Query!
Country [40]
0
0
Belgium
Query!
State/province [40]
0
0
Charleroi
Query!
Country [41]
0
0
Belgium
Query!
State/province [41]
0
0
La Louviere
Query!
Country [42]
0
0
Belgium
Query!
State/province [42]
0
0
Liege
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
Bahia
Query!
Country [44]
0
0
Brazil
Query!
State/province [44]
0
0
Ceará
Query!
Country [45]
0
0
Brazil
Query!
State/province [45]
0
0
Distrito Federal
Query!
Country [46]
0
0
Brazil
Query!
State/province [46]
0
0
Goiás
Query!
Country [47]
0
0
Brazil
Query!
State/province [47]
0
0
Minas Gerais
Query!
Country [48]
0
0
Brazil
Query!
State/province [48]
0
0
Parana
Query!
Country [49]
0
0
Brazil
Query!
State/province [49]
0
0
Rio Grande do Sul
Query!
Country [50]
0
0
Brazil
Query!
State/province [50]
0
0
Santa Catarina
Query!
Country [51]
0
0
Brazil
Query!
State/province [51]
0
0
Sao Paulo
Query!
Country [52]
0
0
Brazil
Query!
State/province [52]
0
0
Belo Horizonte
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
British Columbia
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
Ontario
Query!
Country [55]
0
0
Canada
Query!
State/province [55]
0
0
Quebec
Query!
Country [56]
0
0
Canada
Query!
State/province [56]
0
0
Saskatchewan
Query!
Country [57]
0
0
Chile
Query!
State/province [57]
0
0
Santiago
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Bobigny Cedex
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Caen
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Clamart
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Metz
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Nancy
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Nice Cedex 2
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Strasbourg
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Baden-Württemberg
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Bayern
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Hessen
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Niedersachsen
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Nordrhein-Westfalen
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Rheinland-Pfalz
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Schleswig-Holstein
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Berlin
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Hamburg
Query!
Country [74]
0
0
Hong Kong
Query!
State/province [74]
0
0
Hong Kong
Query!
Country [75]
0
0
Hungary
Query!
State/province [75]
0
0
Budapest
Query!
Country [76]
0
0
Hungary
Query!
State/province [76]
0
0
Deszk
Query!
Country [77]
0
0
Hungary
Query!
State/province [77]
0
0
Gyula
Query!
Country [78]
0
0
Hungary
Query!
State/province [78]
0
0
Matrahaza
Query!
Country [79]
0
0
Hungary
Query!
State/province [79]
0
0
Torokbalint
Query!
Country [80]
0
0
Italy
Query!
State/province [80]
0
0
Torino
Query!
Country [81]
0
0
Italy
Query!
State/province [81]
0
0
Bergamo
Query!
Country [82]
0
0
Italy
Query!
State/province [82]
0
0
Genova
Query!
Country [83]
0
0
Italy
Query!
State/province [83]
0
0
Milano
Query!
Country [84]
0
0
Italy
Query!
State/province [84]
0
0
Parma
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
Pavia
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Perugia
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Roma
Query!
Country [88]
0
0
Korea, Republic of
Query!
State/province [88]
0
0
Seoul
Query!
Country [89]
0
0
Netherlands
Query!
State/province [89]
0
0
Noord-Brabant
Query!
Country [90]
0
0
Netherlands
Query!
State/province [90]
0
0
Zwolle
Query!
Country [91]
0
0
Poland
Query!
State/province [91]
0
0
Gdansk
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Krakow
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Olsztyn
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Otwock
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Warszawa
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Wroclaw
Query!
Country [97]
0
0
Puerto Rico
Query!
State/province [97]
0
0
San Juan
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
Moscow
Query!
Country [99]
0
0
Russian Federation
Query!
State/province [99]
0
0
St. Petersburg
Query!
Country [100]
0
0
Spain
Query!
State/province [100]
0
0
Alicante
Query!
Country [101]
0
0
Spain
Query!
State/province [101]
0
0
Aragón
Query!
Country [102]
0
0
Spain
Query!
State/province [102]
0
0
Madrid
Query!
Country [103]
0
0
Spain
Query!
State/province [103]
0
0
Barcelona
Query!
Country [104]
0
0
Spain
Query!
State/province [104]
0
0
Pontevedra
Query!
Country [105]
0
0
Spain
Query!
State/province [105]
0
0
Zamora
Query!
Country [106]
0
0
Sweden
Query!
State/province [106]
0
0
Gävle
Query!
Country [107]
0
0
Sweden
Query!
State/province [107]
0
0
Stockholm
Query!
Country [108]
0
0
Sweden
Query!
State/province [108]
0
0
Uppsala
Query!
Country [109]
0
0
Taiwan
Query!
State/province [109]
0
0
Taichung
Query!
Country [110]
0
0
Taiwan
Query!
State/province [110]
0
0
Taipei
Query!
Country [111]
0
0
Taiwan
Query!
State/province [111]
0
0
Taoyuan
Query!
Country [112]
0
0
United Kingdom
Query!
State/province [112]
0
0
Devon
Query!
Country [113]
0
0
United Kingdom
Query!
State/province [113]
0
0
Dorset
Query!
Country [114]
0
0
United Kingdom
Query!
State/province [114]
0
0
Leicestershire
Query!
Country [115]
0
0
United Kingdom
Query!
State/province [115]
0
0
London
Query!
Country [116]
0
0
United Kingdom
Query!
State/province [116]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bayer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00300885
Query!
Trial related presentations / publications
Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrao Miziara JE, Balint B, De Marinis F, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Apr 10;28(11):1835-42. doi: 10.1200/JCO.2009.26.1321. Epub 2010 Mar 8.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bayer Study Director
Query!
Address
0
0
Bayer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Scagliotti G, Novello S, von Pawel J, Reck M, Pere...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT00300885
Download to PDF